Two months after making an unsolicited offer of US$120 per share for the company, Amgen has succeeded in its bid to acquire Onyx Pharmaceuticals in order to expand its portfolio of cancer drugs. The two companies have agreed on a price of US$125 per share, which values Onyx at US$10.4 B. The key driver of the deal is Kyprolis® (carfilzomib), which was approved by the US FDA in July 2012 for the treatment of relapsed and refractory multiple myeloma and which has been forecast to achieve peak annual sales in excess of US$2 B.